



May 6<sup>th</sup>, 2022

## **Northview Announces Investment into Total Flow Medical**

Northview Lifesciences is pleased to announce that the 3.5M USD Seed financing for Total Flow Medical has closed oversubscribed at 4.1M USD. Northview will be participating in the Seed financing of Total Flow Medical as lead investor. This raise will advance their first product through to regulatory approval in preparation for commercialization. Total Flow Medical is addressing the unpredictable complication of ischemic and reperfusion injuries occurring during cardiopulmonary bypass procedures. With their patent-pending arterial cannula, clinicians will be able to provide blood flow to a patient's lower leg while undergoing extracorporeal circulation.

**Northview LifeSciences Advancing the Business of Science**

